Glenmark Specialty SA a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd (BSE: 532296 | NSE: GLENMARK), has launched RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and above.
The launch follows regulatory approval from Brazil’s Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA), earlier this year. RYALTRIS is a combination nasal spray containing olopatadine hydrochloride, an antihistamine, and mometasone furoate, a corticosteroid.
According to the company, the launch introduces the first olopatadine-containing intranasal combination therapy in Brazil. The product combines the two active ingredients in a single nasal spray and provides a dual-action treatment option for symptoms associated with allergic rhinitis.
Allergic rhinitis is a common chronic condition in Brazil. Glenmark estimates that it affects around 20% to 30% of the country’s population, equivalent to approximately 40 million to 60 million people. The company said the disease burden highlights the requirement for treatment options that address the symptoms of allergic rhinitis.
Marco Cerato, Executive Vice President and Global Head – Innovative Business, Glenmark Pharmaceuticals, said, “The launch of RYALTRIS® in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach. As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals.”
RYALTRIS is Glenmark’s first globally commercialised branded innovative product. The medicine has received approval in 57 markets worldwide, including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. The Brazilian launch expands the availability of Glenmark’s respiratory portfolio in Latin America and adds another market to the product’s international commercial presence. The company said the expansion forms part of its efforts to increase access to differentiated therapies across global markets.
Glenmark Pharmaceuticals is a research-led pharmaceutical company focused on innovation and access to medicines. Its portfolio covers branded, innovative, generic and consumer health products, with a focus on respiratory, dermatology and oncology. The company operates 11 manufacturing facilities across four continents and has six research and development centres. Its commercial operations extend across more than 80 countries.
Glenmark’s global respiratory portfolio includes RYALTRIS, which has been developed as a combination therapy for allergic rhinitis. The company continues to expand the product’s availability through regulatory approvals and launches in international markets. Glenmark said its research and development and manufacturing capabilities support its strategy of developing and commercialising pharmaceutical products across its focus areas. The company’s international presence includes markets across North America, Europe, Asia, Latin America and other regions. The launch of RYALTRIS in Brazil follows its regulatory approval in the country and further expands the geographic reach of Glenmark’s innovative respiratory portfolio.
